Edition:
United States

Quidel Corp (QDEL.O)

QDEL.O on Nasdaq

20.85USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$20.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
128,753
52-wk High
$22.67
52-wk Low
$13.21

Latest Key Developments (Source: Significant Developments)

Quidel Corp receives FDA clearance for amplivue trichomonas assay
Tuesday, 17 Mar 2015 01:15pm EDT 

Quidel Corp:Receives clearance from United States Food and Drug Administration (FDA) to market its amplivue trichomonas assay for detection of nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic female patients.Says this molecular assay aids in diagnosis of trichomoniasis, a sexually transmitted disease attributable to infection by trichomonas vaginalis parasite.  Full Article

Quidel Corporation receives simultaneous FDA clearance
Wednesday, 17 Dec 2014 06:45pm EST 

Quidel Corporation:Says that it has received marketing clearance and CLIA waiver by the United States Food and Drug Administration (FDA) for its Sofia Strep A+ Fluorescent Immunoassay (FIA) for the rapid detection of infections by Group A Streptococcus bacteria.  Full Article

Quidel Corporation issuing 3.25 pct senior convertible notes due 2020 - Form 8-K
Monday, 8 Dec 2014 11:24am EST 

Quidel Corporation:Issuing $172,500,000 aggregate principal amount of its 3.25 pct senior convertible notes due 2020.Under the indenture, dated as of Dec. 01, between company and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by First Supplemental Indenture, dated as of Dec. 08, between company and the Trustee.Notes will be senior unsecured obligations of company.Notes will bear interest at a rate of 3.25 pct per year, payable semiannually in arrears on June 15 and Dec. 15 of each year, beginning on June 15, 2015.Notes will mature on Dec. 15, 2020, unless earlier converted or repurchased.Company may not redeem the Notes prior to the Maturity Date.  Full Article

Quidel Corporation announces pricing of $150 million convertible senior notes offering
Tuesday, 2 Dec 2014 11:10pm EST 

Quidel Corporation:Announces pricing of its previously announced underwritten public offering of $150 million aggregate principal amount of its 3.25 pct. convertible senior notes due 2020.Says Quidel has granted the underwriters of the notes a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the notes, solely to cover over-allotments, if any.BofA Merrill Lynch and J.P. Morgan are acting as book-running managers for the proposed notes offering.Says the offering is expected to close on or around Dec. 8, 2014.  Full Article

Quidel announces proposed offering of $150 million of convertible senior notes
Monday, 1 Dec 2014 04:34pm EST 

Quidel Corporation:Proposes underwritten public offering of $150 mln aggregate principal amount of its convertible senior notes due 2020.Quidel also expects to grant the underwriters of the notes a 30-day option to purchase up to an additional $22.5 mln aggregate principal amount of the notes, solely to cover over-allotments, if any.BofA Merrill Lynch and J.P. Morgan will act as book-running managers for the proposed notes offering.Intends to use the net proceeds for working capital and other general corporate purposes.  Full Article

Quidel Corp receives FDA clearance for Lyra Molecular PCR Assay
Wednesday, 15 Oct 2014 02:00pm EDT 

Quidel Corp:Received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay.Says it is a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens.  Full Article

Quidel Corp receives FDA clearance for Lyra Molecular PCR Assay
Monday, 13 Oct 2014 02:00pm EDT 

Quidel Corp:Received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus (HAdV) viral DNA isolated from nasal swab and nasopharyngeal swab specimens.  Full Article

BRIEF-Quidel Q1 GAAP loss per share $0.11

* Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S